anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain permission fruit juice free from astringent taste and agreeable to take, easily in high yield, by mixing permission fruit with sugar or salt, and collecting the exuded juice. CONSTITUTION:A persimmon fruit is washed with water and dried and the calyx and skin are removed therefrom, or a persimmon fruit is crushed after the removal of the calyx. The persimmon fruit processed above is added with preferably 10wt% sugar (e.g. sucrose) or preferably 5wt% salt (e.g. calcium chloride), and stored for 10 days e.g. at <=15 deg.C to obtain the objective fruit juice.
A growing number of re-infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in previously immunized individuals has sparked discussions about the potential need for a booster vaccine dosage to counteract declining antibody levels and new strains. The protective immunity produced by vaccinations, and past illnesses relies on immunological memory. CD4 + T cells, CD8 + T cells, B cells, and long-lasting antibody responses are all components of the adaptive immune system that can generate and maintain this immunological memory. Since novel mutant variants have emerged one after the other, the world has been hit by repeated waves. Various vaccine formulations against SARS-CoV-2 have been administered across the globe. Thus, estimating the efficacy of those vaccines against gradually developed mutant stains is the essential parameter regarding the fate of those vaccine formulations and the necessity of booster doses and their frequency. In this review, focus has also been given to how vaccination stacks up against moderate and severe acute infections in terms of the longevity of the immune cells, neutralizing antibody responses, etc. However, hybrid immunity shows a greater accuracy of re-infection of variants of concern (VOCs) of SARS-CoV-2 than infection and immunization. The review conveys knowledge of detailed information about several marketed vaccines and the status of their efficacy against specific mutant strains of SARS-CoV-2. Furthermore, this review discusses the status of immunological memory after infection, mixed infection, and vaccination.
Accumulating evidence has indicated an increased risk of acute pancreatitis in individuals with inflammatory bowel disease (IBD); however, the establishment of a clear and direct causal connection between IBD and acute pancreatitis remains uncertain. Utilizing genetic data from publicly accessible genome-wide association studies (GWAS), we conducted a 2-sample MR analysis to identify the associations between IBD, ulcerative colitis (UC), Crohn disease (CD), and acute pancreatitis risk. Rigorous quality control steps ensured the selection of eligible single nucleotide polymorphisms (SNPs) with strong associations to IBD. The primary estimation used the inverse-variance weighted method. We also assessed heterogeneity, potential pleiotropy, and conducted sensitivity analyses. The direction of causality was confirmed using the Steiger test. The MR analysis showed that IBD increased the risk of acute pancreatitis (IVW: OR = 1.032, 95% CI: 1.006-1.06, P = .015). Among the subgroup of IBD, CD (IVW: OR = 1.034, 95% CI: 1.008-1.06, P = .007) indicates a significant increase in the risk of acute pancreatitis compared to UC (IVW: OR = 1.02, 95% CI: 0.99-1.051, P = .189). The MR analysis assessing the association between CD and acute pancreatitis showed no evidence of heterogeneity or horizontal pleiotropy. Likewise, the leave-one-out (LOO) method indicated no significant influence of any individual SNP on the overall findings. In addition, the Steiger direction test revealed that CD was the cause for increased risk of acute pancreatitis, but not vice versa. In summary, this research pioneers in proposing a causal relationship between CD and acute pancreatitis among the European population.
The invention discloses an influenza virus vaccine strain. The invention discloses a virus. The amino acid sequence of each of PB2 protein, PB1 protein, PA protein, NP protein, NA protein, M1 protein, M2 protein, NS1 protein, NS2 protein and HA protein are respectively shown as follows: SEQ ID No. 26, SEQ ID No. 34, SEQ ID No. 33, SEQ ID No. 21, SEQ ID No. 29, SEQ ID No. 27, SEQ ID No. 28, SEQ ID No. 31, SEQ ID No. 32 and SEQ ID No. 16. The recombinant virus disclosed by the invention can be rapidly and stably proliferated in high yield. Compared with the method for preparing the vaccine by utilizing the chicken embryo, the recombinant virus has obvious advantage, and the inactivated vaccine of the recombinant virus can be used for protecting animals against the infection of influenza virus.
PROBLEM TO BE SOLVED: To prepare an antisuntan cosmetic, remarkably improved in effects of an ultraviolet light absorber even if the amount thereof is not increased and excellent even in water resistance by using a specific siliconized polysaccharide compound and an organic ultraviolet light absorber in combination. SOLUTION: This antisuntan cosmetic comprises a siliconized polysaccharide compound represented by the formula [Glu is a saccharide residue of a polysaccharide compound; X is a bivalent bonding group, R<1> is a monovalent organic group; R<2> to R<4> are each a monovalent oganic group or a siloxy represented by OSiR<5> R<6> R<7> (R<5> to R<7> are each a monovalent organic group); (a) is 0-2]. A compound represented by formula II is preferred in the compound represented by formula I. A compound in which Glu is a glucose residue of pullulan or (a) is 0 and R<2> to R<4> are each methyl or Y is a group represented by (CH2 )3 is preferred in the compounds represented by formulae I and II. The amount of the blended siliconized polysaccharide compound in the cosmetic is usually 0.1-50wt.%, especially preferably 3-10wt.%.  The amount of the organic ultraviolet light absorber is 15wt.% in the case of, e.g. homomenthyl salicylate.
Participants will utilize a daily sleep program available within a widely used smartphone app, which includes seven soundtracks (10-15min each) for guided mindfulness practice at bedtime. Techniques include breathing exercises, mental imagery, awareness of body and mind, and muscle and body relaxation.
The present invention provides novel humanized monoclonal and bispecific antibodies, and fragments and derivatives thereof, which specifically bind to IL-4 and/or IL-13. Some of the anti-IL-4 and/or IL-13 mono- or bispecific antibodies, and fragments thereof, can be altered to prevent intrachain disulfide bond formation resulting in a molecule that is stable through manufacturing and use in vivo. The antibodies of the present invention neutralize IL-4 and/or IL-13 activity in the biological assays described herein. The invention includes the amino acid sequences of the variable heavy and light chain of the antibodies and their corresponding nucleic acid sequences. Another embodiment of the present invention includes the cell lines and vectors harboring the antibody sequences of the present invention. Another embodiment of the present invention is the use of the antibodies for the preparation of a pharmaceutical composition for the treatment of diseases and disorders associated with IL-4 and/or IL-13 function and metabolism. In particular, the present invention relates to the treatment of cancer, autoimmune deficiencies and diseases caused by or characterized by inflammation, such as allergic asthma and dermatitis. Additional features and advantages are described herein, and will be apparent from, the following Detailed Description and the figures.
In individuals diagnosed with subarachnoid hemorrhage (SAH), fevers have been shown to have detrimental micro and macroscopic effects on the brain that can ultimately cause secondary brain injury. The anti-pyretic effects of oral acetaminophen have been studied in critically ill patients but no study has been able to compare these effects to the IV form of acetaminophen also known as OFIRMEV. The investigators wish to explore the notion that IV acetaminophen will be more effective than enteral acetaminophen in reducing the incidence of non-infectious fevers in critically ill patients. In addition, the investigators propose to study the levels of inflammatory cytokines after administration of IV or enteral acetaminophen, as well as, determine the incidence of vasospasm in SAH patients treated with IV acetaminophen. Currently, external ventricular drain (EVD) placement is the "standard of care" in patients who present with SAH and altered mental status/coma. The presence of an EVD allows for continuous sampling and removal of cerebral spinal fluid (CSF) as necessary to alleviate dangerous elevations in intracranial pressure. This clinical scenario allows for a unique, continuous outlet to access the CSF, without placing patients at risk, and without further invasive procedures (i.e. repeated spinal taps). These samples of CSF can be assayed for levels of acetaminophen, as well as inflammatory markers of fever which include interleukin-1 (IL-1), interleukin-6 (IL-6), and thromboxane-2 (TXA-2), in patients selected to be given enteral or IV acetaminophen.
Adipose tissue macrophages (ATMs) are key players in the development of obesity and associated metabolic inflammation, which contributes to systemic metabolic dysfunction, and understanding the interaction between macrophages and adipocytes is crucial for developing novel macrophage-based strategies against obesity. Here, we found that Legumain (Lgmn), a well-known lysosomal cysteine protease, is expressed mainly in the ATMs of obese mice. To further define the potential role of Lgmn-expressing macrophages in the generation of an aberrant metabolic state, LgmnF/F; LysMCre mice, which do not express Lgmn in macrophages, were maintained on a high-fat diet (HFD), and metabolic parameters were assessed. Macrophage-specific Lgmn deficiency protects mice against HFD-induced obesity, diminishes the quantity of proinflammatory macrophages in obese adipose tissues, and alleviates hepatic steatosis and insulin resistance. By analysing the transcriptome and proteome of murine visceral white adipose tissue (vWAT) after HFD feeding, we determined that macrophage Lgmn deficiency causes changes in lipid metabolism and the inflammatory response. Furthermore, the reciprocity of macrophage-derived Lgmn with integrin α5β1 in adipocytes was tested via colocalization analyses. It is further demonstrated in macrophage and adipocyte coculture system that macrophage derived Lgmn bound to integrin α5β1 in adipocytes, therefore attenuating PKA activation, downregulating lipolysis-related proteins and eventually exacerbating obesity development. Overall, our study identified Lgmn as a previously unrecognized regulator involved in the interaction between ATMs and adipocytes contributing to diet-induced obesity and suggested that Lgmn is a potential target for treating metabolic disorders.
OBJECTIVE: Even though several German children's hospitals offer integrative, anthroposophic medical therapies in addition to the standard medical care, guidelines for these anthroposophic therapies are still rare. Therefore, we investigated the feasibility of implementing a published, consensus-based guideline for the treatment of children with acute gastroenteritis (aGE) with anthroposophic therapies in the community hospital Herdecke.
DESIGN: A prospective case series of paediatric patients (≤18 years) with an aGE admitted to the department of integrative paediatrics of the community hospital Herdecke was conducted. Demographic, clinical and therapeutic data was recorded at initial presentation and at follow-up visits. Physicians were surveyed with a questionnaire to evaluate feasibility of implementing the guideline.
RESULTS: Sixty-two patients (0-15 years; 22 male, 40 female) were included in the case series. All patients received some form of anthroposophic therapy. The most frequently used remedies were Geum urbanum, Nux vomica and Bolus alba comp. Treating physicians showed a high adherence to the expert-based consensus guideline in their prescribed therapies. All physicians stated that they were familiar with the guideline and used the recommendation to inform their therapy decision. Suitability for daily use and effectiveness in treating the main symptoms of aGE were highly scored by the physicians.
CONCLUSION: The consensus-based guideline of anthroposophic therapies for aGE in children was successfully implemented and found to be useful for physicians in clinical practice.
A total of 20 participants are going to be enrolled in this study; 10 participants smoke hookah and 10 participants are exposed to second hand hookah smoke for 2 hours in NYC hookah bars. Subjects in the control group will also be paired as they were for the hookah bar visit but will visit a control location, where they will be asked to consume a similar amount of food and drink at a wine bar. Pulmonary function, cardiovascular changes, and blood and urine markers of inflammatory mediators before, immediately after and 24 hours after the participants' visits to hookah bars and wine bars will be examined. Air quality monitoring will also be performed at the hookah bar and at the control location. Physiological changes will be assessed by measuring pulmonary function, blood pressure, heart rate, and blood oxygenation status. To determine the extent of tobacco exposure and associated inflammatory changes from secondhand hookah smoke, investigators will measure blood inflammatory biomarkers, oxidative stress, gene expression, tobacco-related carcinogenic metabolites, and exhaled carbon dioxide levels.
A polylactide in a purified state, which meets the requirements of  - the colour strengths of reference solutions B2 - B9 of the brown colour test of the European Pharmacopoeia, 2nd       Edition (1980) part I, Section V, 6.2 and - containing one or more metals in cationic form, the metal ion(s) having a concentration of at most 10 ppm.   The polylactide is especially suitable for use as microparticles or implants, and contains preferably a hydrophilic drug, like octreotide or a lipophilic drug like bromocriptine. The metal ion is preferably Sn<++>, derived from the catalyst used to prepare the polylactide, e.g. the tin (II) salt of 2-ethyl-hexanoic acid. The purified polylactides may be prepared by contacting a solution of the impure polylactide with a matrix having on its surface carboxylic groups, e.g. active charcoal, and isolating the purified polymer from the eluate. The isolation step may further include ultrafiltration. The polylactide preferably contains glycolide units and preferably has a mean molecular weight of 10,000 to 200,000 and a polydispersity of 1.2 to 3.0.
The invention relates to a medicine for curing oral diseases, in particular to a pharmaceutical composition for curing laryngitis. The pharmaceutical composition is composed of the following effective components by weight: 51 to 73 parts of docynia fruit, 17 to 22 parts of fructus phyllanthi fruit, 5 to 8 parts of paris polyphylla, 15 to 23 parts of dendrobium candidum, and 1 part of honey. The invention further provides a method for preparing the pharmaceutical composition for curing laryngitis. The pharmaceutical composition is high in curative effect and efficiency; and honey is taken as guiding drug, so as to reduce the bitter taste of the pharmaceutical composition (namely, throat smoothing buccal tablet), which ensures that a patient can take the buccal tablet more comfortably. The buccal tablet is very obvious in laryngitis curing effect; and for 97 clinical trials, the buccal tablet is effective in 93 clinical trials, the effective rate is up to 95.9 percent, and patients in 37clinical trials are cured. Therefore, the clinical trials show that the throat smoothing buccal tablet is obvious in laryngitis curing effect.
Wounds refer to physical injuries in which the integrity of the skin or other body organs is disturbed. Wound care includes proper management and treatment of the injuries to promote healing while avoiding infection. Here, a core-shell scaffold is developed comprising polyethylene glycol/silk fibroin-chitosan nanoparticles loaded with curcumin. Chitosan nanoparticles and PEG/Silk fibrous scaffold were synthesized by a microfluidic system and electrospinning technique, respectively. TEM, DLS, and FTIR techniques were used to examine the nanoparticles; whereas nanofibers were characterized by SEM, TEM, and FTIR. Drug loading and release from nanoparticles and scaffolds were assessed by optical spectroscopy. MTT assay and hemolysis test were performed to examine the toxicity of the scaffolds. The hydrophobicity or hydrophilicity of nanofibers was explored by the contact angle test. Scaffolds were examined on the full-thickness wound created on Wistar rats, followed by histological analyses and coagulation tests. The results of FTIR, TEM, and SEM indicated the proper distribution of nanoparticles and core-shell scaffold. The drug loading was about 3 %. About 80 % of the drug was released in the first 7 days. Scaffolds showed hydrophobic properties (114.63° ± 3.6) with no cytotoxicity. The proposed scaffold was able to close 94 % of the wound era after 14 days in the animal model and positively affected re-epithelization and angiogenesis. Moreover, nanofibers containing chitosan nanoparticles exhibited a proper blood coagulation ability in the tail cut model. Finally, it was found that this scaffold, in addition to a biological dressing, can be considered as a drug delivery, and according to the results obtained, this dressing has hydrophobic properties and has also shown good performance against superficial bleeding coagulation. And it has not shown any cytotoxicity for red blood cells and mesenchymal stem cells.
This group of participants will receive Active Release Therapy, a kind of soft tissue mobilization along with routine physical therapy. The protocol will be given to the participants for two weeks (6 sessions on alternate days, 3 session per week). Each session will be of 60 minutes. The data will be collected before applying intervention, at first week and at 2nd week.
In cases of overdosage, (including relative overdose due to hepatic dysfunction), urinary retention, paralytic ileus and CNS depression may occur. Children may be more sensitive to CNS effects than adults. Clinical trials have demonstrated that a slurry of activated charcoal administered promptly after ingestion of loperamide hydrochloride can reduce the amount of drug which is absorbed into the systemic circulation by as much as ninefold. If vomiting occurs spontaneously upon ingestion, a slurry of 100 grams of activated charcoal should be administered orally as soon as fluids can be retained.

If vomiting has not occurred, gastric lavage should be performed followed by administration of 100 grams of the activated charcoal slurry through the gastric tube. In the event of overdosage, patients should be monitored for signs of CNS depression for at least 24 hours.

If symptoms of overdose occur, naloxone can be given as an antidote. If responsive to naloxone, vital signs must be monitored carefully for recurrence of symptoms of drug overdose for at least 24 hours after the last dose of naloxone.

In view of the prolonged action of loperamide and the short duration (one to three hours) of naloxone, the patient must be monitored closely and treated repeatedly with naloxone as indicated. Since relatively little drug is excreted in the urine, forced diuresis is not expected to be effective for loperamide hydrochloride overdosage.

In clinical trials an adult who took three 20 mg doses within a 24 hour period was nauseated after the second dose and vomited after the third dose. In studies designed to examine the potential for side effects, intentional ingestion of up to 60 mg of loperamide hydrochloride in a single dose to healthy subjects resulted in no significant adverse effects.
BACKGROUND: Ventral hernia repair is a common elective general surgery procedure among older patients, a population at greater risk of complications. Prior research has demonstrated improved quality of life in this population despite increased risk of complications. This study sought to assess the relationship between post-ventral hernia repair quality of life and patient frailty. We hypothesized that frail patients would report smaller gains in quality of life compared to the non-frail group.
METHODS: The Abdominal Core Health Quality Collaborative was used to identify a cohort of patients 65 years of age or older undergoing elective ventral hernia repair from 2018 to 2022. Patients were categorized based on their modified frailty index scores as not frail/prefrail, frail, and severely frail. Quality of life was assessed using a patient-reported 12-item scale preoperatively, 30 days, 6 months, and 1 year postoperatively.
RESULTS: A total of 3,479 patients were included: 30.93% non-frail, 47.17% frail, and 21.90% severely frail. Severely frail patients had lower quality of life scores at baseline (P = .001) but reported higher quality of life at both 30 days (1.24 points higher, 95% confidence interval (-1.51, 2.52), P = .010) and 6 months (0.92 points higher, 95% confidence interval (-2.29, 4.13), P = .005). Severely frail patients had higher rates of surgical site complications (P < .001) but no difference in 30-day readmissions.
CONCLUSION: Our results found that frail patients reported the greatest increase in quality of life 1 year from baseline, showing that they, when selected appropriately, can gain equal benefits and have similar surgical outcomes as their non-frail counterparts.
OBJECTIVES: Infections represent a major risk for critically ill neonatal and paediatric patients requiring extracorporeal life-saving support such as extracorporeal membrane oxygenation (ECMO) and/or continuous renal replacement therapies (CRRT). Patient outcomes rely on achieving target antimicrobial concentrations. In critically ill adults on extracorporeal support, suboptimal antimicrobial concentrations have been shown to be common. Our objective was to systematically review antimicrobial pharmacokinetic studies in critically ill term neonatal and paediatric patients receiving ECMO and/or CRRT and compare them to similar cohorts of patients not receiving ECMO or CRRT.
METHODS: Studies published between 1990 and 2022 were identified through systematic searches in PUBMED, Embase, Web of Science, Medline, Google Scholar and CINAHL. Studies were included which provided antimicrobial pharmacokinetic parameters (volume of distribution and clearance) in the neonatal and paediatric patients receiving ECMO and/or CRRT. Studies were excluded if no antimicrobial pharmacokinetic parameters were described or could be calculated.
RESULTS: Forty-four pharmacokinetic studies were identified describing 737 patients, with neonatal patients recruited in 70% of the ECMO studies and <1% of the CRRT studies. Of all the studies, 50% were case reports or case series. The pharmacokinetics were altered for gentamicin, daptomycin, ceftolozane, micafungin, voriconazole, cefepime, fluconazole, piperacillin, and vancomycin, although considerable patient variability was described.
CONCLUSION: Significant gaps remain in our understanding of the pharmacokinetic alterations in neonatal and paediatric patients receiving ECMO and CRRT support.
Participants in the TAU control group received treatments as usual for 4 weeks. No additional sleep intervention was provided. All participants were required to complete the subjective and objective assessments.